MedTrace Logo

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

NCT07461454 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2026-03-10

No results posted yet for this study

Summary

The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who had failed at least one line of chemotherapy.

Conditions

Interventions

DRUG

YL202

IV infusion on day 1 of each 21 day cycle

DRUG

Eribulin

1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle

DRUG

Capecitabine

1000 or 1250 mg/m2, po, bid, from day 1 to Day 14 of each 21 day cycle

DRUG

Gemcitabine

1000 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle

DRUG

Vinorelbine

25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle

DRUG

Sacituzumab govitecan

10 mg/kg, IV infusion on day 1 and Day 8 of each 21 day cycle

Sponsors & Collaborators

  • MediLink Therapeutics (Suzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-10
Primary Completion
2027-12-31
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07461454 on ClinicalTrials.gov